PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund grew its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 30.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 189,154 shares of the company’s stock after acquiring an additional 44,324 shares during the period. New York State Common Retirement Fund owned about 0.36% of PROCEPT BioRobotics worth $15,231,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. KRS Capital Management LLC raised its holdings in PROCEPT BioRobotics by 0.5% during the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock worth $3,741,000 after buying an additional 225 shares during the period. KBC Group NV boosted its stake in PROCEPT BioRobotics by 32.6% in the 3rd quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after purchasing an additional 376 shares during the period. Raleigh Capital Management Inc. purchased a new position in PROCEPT BioRobotics during the 4th quarter worth approximately $32,000. Nisa Investment Advisors LLC raised its stake in PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock valued at $89,000 after purchasing an additional 713 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of PROCEPT BioRobotics in the third quarter valued at $64,000. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $62.25 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The firm has a market cap of $3.25 billion, a PE ratio of -31.92 and a beta of 1.03. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81. The firm’s 50 day moving average price is $76.53 and its 200 day moving average price is $79.99.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PRCT. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Morgan Stanley began coverage on PROCEPT BioRobotics in a report on Monday, December 2nd. They issued an “overweight” rating and a $105.00 target price on the stock. Jefferies Financial Group started coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They set a “hold” rating and a $95.00 price target for the company. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $97.86.

Insider Activity

In related news, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total value of $2,568,844.06. Following the transaction, the chief executive officer now owns 152,762 shares in the company, valued at $14,851,521.64. This trade represents a 14.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Alaleh Nouri sold 28,092 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the transaction, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at $5,096,605.36. This represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,935 shares of company stock worth $7,882,089. 17.40% of the stock is owned by corporate insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).